Antibody and Immunoglobulin Response to Antirabies Vaccination in Man

Cho, Han C.; Fenje, P; Sparkes, John D.

doi:10.1128/iai.6.4.483-486.1972

Cited by 6 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Group C, the rVNA increased significantly compared to day 13 ( p < 0.01), with a GMT of 74.80 IU/mL. The results demonstrated a strong anti-rabies response that occurred within 3 weeks, similar to previous studies with inactivated rabies vaccines [20,21]. As shown in Figure 2a, the rVNA in Group A mice was always negative, <0.02 IU/mL; while the mean rVNA in Group B mice increased until day 47, and then subsided, but was still above the 0.5 IU/mL threshold, an arbitrary level representing adequate rabies vaccination.…”

Section: Resultssupporting

confidence: 85%

Inactivated Rabies Virus-Vectored Immunocontraceptive Vaccine in a Thermo-Responsive Hydrogel Induces High and Persistent Antibodies against Rabies, but Insufficient Antibodies against Gonadotropin-Releasing Hormone for Contraception

Yang

Kling

et al. 2019

Vaccines

View full text Add to dashboard Cite

Rabies is preventable through vaccination, but the need to mount annual canine vaccination campaigns presents major challenges in rabies control and prevention. The development of a rabies vaccine that ensures lifelong immunity and animal population management in one dose could be extremely advantageous. A nonsurgical alternative to spay/neuter is a high priority for animal welfare, but irreversible infertility in one dose has not been achieved. Towards this goal, we developed a rabies virus-vectored immunocontraceptive vaccine ERA-2GnRH, which protected against rabies virus challenge and induced >80% infertility in mice after three doses in a live, liquid-vaccine formulation (Wu et al., 2014). To improve safety and use, we formulated an inactivated vaccine in a thermo-responsive chitosan hydrogel for one-dose delivery and studied the immune responses in mice. The hydrogel did not cause any injection site reactions, and the killed ERA-2GnRH vaccine induced high and persistent rabies virus neutralizing antibodies (rVNA) in mice. The rVNA in the hydrogel group reached an average of 327.40 IU/mL, more than 200 times higher than the liquid vaccine alone. The Gonadotropin-releasing hormone (GnRH) antibodies were also present and lasted longer in the hydrogel group, but did not prevent fertility in mice, reflecting a possible threshold level of GnRH antibodies for contraception. In conclusion, the hydrogel facilitated a high and long-lasting immunity, and ERA-2GnRH is a promising dual vaccine candidate. Future studies will focus on rabies protection in target species and improving the anti-GnRH response.

show abstract

Section: Resultssupporting

confidence: 85%